Therapeutic | Iscalimab |
Target | CD40 |
Heavy Chain | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYEESNRYHADSVKGRFTISRDNSKITLYLQMNSLRTEDTAVYYCARDGGIAAPGPDYWGQGTLVTVSS |
Light Chain | DIVMTQSPLSLTVTPGEPASISCRSSQSLLYSNGYNYLDWYLQKPGQSPQVLISLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQARQTPFTFGPGTKVDIR |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-II |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2017 |
INN Year Recommended | 2018 |
Companies Involved | Novartis, XOMA |
Conditions Approved | na |
Conditions Active | Graves' disease, Lupus nephritis, Myasthenia gravis, Renal transplant rejection, Sjogren's syndrome, Systemic lupus erythematosus |
Conditions Discontinued | Rheumatoid arthritis |
Notes |